OKYO Pharma Ltd - New
Research OKYO Pharma Ltd - New (OKYO) on Bullrun: market cap USD 74.52M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerOKYO
- ExchangeNASDAQ
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 74.52M
- Financial periodFY2026
- RevenueUSD 0
- Net income-USD 8.95M
- Free cash flow-USD 5.94M
Valuation Snapshot
latest market cap is USD 74.52M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | USD 0 | -USD 8.95M | -USD 5.94M | n/a | -0.24 | USD 14.59M | n/a | USD 12.34M |
| FY2025 | USD 0 | -USD 4.71M | -USD 1.81M | n/a | -0.12 | USD 1.56M | USD 185.80K | -USD 5.55M |
| FY2024 | USD 0 | -USD 16.83M | -USD 9.49M | n/a | -0.57 | USD 826.85K | USD 1.81K | -USD 5.88M |
| FY2023 | USD 0 | -USD 13.27M | -USD 7.70M | n/a | -0.61 | USD 4.05M | USD 2.22M | -USD 2.05M |
| FY2022 | USD 0 | -USD 5.43M | -USD 5.47M | n/a | -0.36 | USD 2.70M | USD 0 | USD 2.95M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 74.52M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 79.60M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 39.03M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 58.83M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 41.58M | n/a | n/a | n/a |
About OKYO Pharma Ltd - New
OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is OKYO Pharma Ltd - New's market cap?
OKYO Pharma Ltd - New's market capitalization is USD 74.52M.
What does OKYO Pharma Ltd - New do?
OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.